Leading BioSciences Appoints Greg Doyle as Chief Executive Officer

SAN DIEGO, June 23, 2016 /PRNewswire/ -- Leading BioSciences Inc., a clinical-stage biopharmaceutical company advancing programs that address medical conditions resulting from a breakdown of the mucosal barrier, today announced that it has appointed Greg Doyle as chief executive officer. Mr. Doyle, a long-standing member of Leading BioSciences' executive management team and board of directors, previously served as chief operations officer and chief financial officer. He will provide continued leadership and strategic direction to the company's pipeline development, clinical research and financing activities. Mr. Doyle succeeds Clark Straw, who will remain as chairman of the board.

"Greg has been a cornerstone of leadership at Leading BioSciences since the company's early days in 2010. He has driven a steady increase in shareholder value by leading the company's capital formation, operational maturity and team development, and helping to advance our lead drug candidate, LB1148, into Phase 2 clinical trials for multiple high-need indications," said Mr. Straw. "Greg will continue to build on our founding vision to become the premier biopharmaceutical company focused on disease states caused by the mucosal barrier breakdown."

Mr. Doyle, serving as COO and CFO, led efforts to raise over $20 million in private capital over the past six years. In addition to his financial acumen, his strategic decision making has led to mission critical discoveries in new indications for the company's lead drug, LB1148, as well as issuance of key company patents. In addition, Mr. Doyle's leadership has helped shape the design of numerous patient trials and build a team of experienced executives and scientific advisors to fulfill the company's vision.

"I am honored to be at the helm of Leading BioSciences during this critical stage of growth, as we move forward in bringing much-needed treatments to patients with post-operative ileus, surgical adhesions and severe shock," Mr. Doyle said. "My priority is to build upon our strong and productive relationships with shareholders, the investment community and health authorities, as we realize our vision of building shareholder value by delivering strong clinical data and strengthening our intellectual property estate."  

Before joining Leading BioSciences, Mr. Doyle embraced entrepreneurial and senior-level leadership roles in both public and private companies, specializing in strategic management consulting, mergers and acquisitions, new-company formation and the development of early to mid-stage companies. He has held financial evaluation and due diligence roles for dozens of M&A transactions valued at more than $3 billion. He is a former managing partner at early-stage venture capital fund, InLab Ventures, has served as division president for UBICS Corp., and held strategic management consulting roles at both A.T. Kearney and Sapient Corp. Mr. Doyle is also a serial entrepreneur, having founded and sold four different companies since 1990 and successfully raised more than $60 million in seed and Series A and B funds for his own startups.

Mr. Doyle received his Masters of Business Administration from the University of Southern California Marshall School of Business and a Bachelor of Science in finance from Brigham Young University.

About Leading BioSciences Inc.
Leading BioSciences is a clinical-stage biopharmaceutical company advancing a novel therapeutic that addresses the breakdown of the intestinal mucosal barrier — a process believed to drive a range of serious health conditions in need of effective treatment options. With a deep and pioneering scientific understanding of this emerging area of biology, Leading BioSciences has developed a patented approach that can be applied to widespread conditions, including acute shock, multiple organ failure, postoperative ileus and surgical adhesions. Phase 2 clinical trials are underway for Leading BioSciences' investigational drug LB1148, which is supported by a robust base of positive preclinical outcomes and more than $22 million in foundational research backed by the National Institutes of Health. Visit www.leadingbiosciences.com for additional information.

SOURCE Leading BioSciences Inc.

Related Links

http://www.leadingbiosciences.com